The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs

<strong>Background:</strong> Extended-release niacin with laropiprant did not significantly reduce the risk of major vascular events and increased the risk of serious adverse events in HPS2-THRIVE but its net effects on health and healthcare costs are unknown. <strong>Methods an...

詳細記述

書誌詳細
主要な著者: Kent, S, Haynes, R, Hopewell, J, Parish, S, Gray, A, Landray, M, Collins, R, Armitage, J, Mihaylova, B
フォーマット: Journal article
出版事項: American Heart Association 2016

類似資料